To test this premise, we treated either wild-type or GBA1 K198E skin fibroblasts, which are a valid model of PD (Deus et al., 2020; Teves et al., 2018), with the specific LRRK2 inhibitor PF-06447475 (hereafter PF-475) (Henderson et al., 2015). This evidence concerns the gene LRRK2 and Parkinson disease.